PROpranolol for Cerebral Hemorrhage-ASsociated pnEumonia (PRO-CHASE)

Prior treatment

• Previous stroke or pre-onset motor disability (mRS≥1)
• Pregnancy or parturition within previous 30 days or active lactation.
• Immunosuppressant therapy or known immunosuppression.

Other illness

• Subjects is considered a candidate for immediate surgical intervention by the neurosurgery service, including surgical evacuation of hematoma, decompressive craniectomy, minimally invasive aspiration of hematoma, and ventricular shunt or external ventricular drainage for intracerebral hemorrhage into the ventricle.
• Patients with primary intraventricular hemorrhage or cerebral hemorrhage due to a definite cause, such as trauma, vascular malformation, aneurysm, coagulopathy, anticoagulant or antiplatelet drugs, thrombolytic therapy, post-infarction hemorrhagic transformation, hematologic disease, moyamoya disease, primary or metastatic tumor, venous sinus thrombosis, vasculitis, etc.
• Bronchial asthma or chronic obstructive pulmonary disease
• Cardiogenic shock or severe or acute heart failure.
• Degree II-III atrioventricular block or sinus bradycardia or heart rate ≤65/min.
• Severe hepatic or renal insufficiency
• History of Malignancy

Other

• Use of beta blockers (propranolol, metoprolol, sotalol, carvedilol, bisoprolol, atenolol, esmolol, etc.) or reserpine within the last 30 days.
• Known sensitivity to propranolol.
• Currently participating in other interventional clinical trials.

• Age 18 years older and less than 80 years.
• Onset of new neurological deficits within≤24 hours at the time of randomization
• CT scan demonstrates supratentorial parenchymal hemorrhage and volume of hematoma≥10ml .
• Initial NIHSS score of 11 or greater and less than 25 scores.
• Initial GCS score (aggregate of verbal, eye, and motor response scores) of 8 or greater at time of enrollment.
• Admission without infection signs.
• Signed and dated informed consent by the subject, legally authorized representative, or surrogate obtained.